PMC:7074424 / 26880-27257 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"608","span":{"begin":159,"end":167},"obj":"Gene"},{"id":"609","span":{"begin":276,"end":284},"obj":"Gene"},{"id":"612","span":{"begin":20,"end":23},"obj":"Chemical"},{"id":"613","span":{"begin":25,"end":29},"obj":"Chemical"},{"id":"614","span":{"begin":35,"end":39},"obj":"Chemical"},{"id":"615","span":{"begin":78,"end":82},"obj":"Chemical"},{"id":"616","span":{"begin":88,"end":96},"obj":"Disease"},{"id":"617","span":{"begin":220,"end":228},"obj":"Disease"}],"attributes":[{"id":"A608","pred":"tao:has_database_id","subj":"608","obj":"Gene:164045"},{"id":"A609","pred":"tao:has_database_id","subj":"609","obj":"Gene:164045"},{"id":"A612","pred":"tao:has_database_id","subj":"612","obj":"MESH:D000255"},{"id":"A613","pred":"tao:has_database_id","subj":"613","obj":"MESH:C026600"},{"id":"A614","pred":"tao:has_database_id","subj":"614","obj":"MESH:C024107"},{"id":"A616","pred":"tao:has_database_id","subj":"616","obj":"MESH:D064420"},{"id":"A617","pred":"tao:has_database_id","subj":"617","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}

{"project":"2_test","denotations":[{"id":"32201449-20071563-47217144","span":{"begin":84,"end":86},"obj":"20071563"},{"id":"32201449-16611118-47217145","span":{"begin":230,"end":232},"obj":"16611118"},{"id":"32201449-27064001-47217146","span":{"begin":374,"end":376},"obj":"27064001"},{"id":"T33859","span":{"begin":84,"end":86},"obj":"20071563"},{"id":"T41240","span":{"begin":230,"end":232},"obj":"16611118"},{"id":"T97464","span":{"begin":374,"end":376},"obj":"27064001"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T835","span":{"begin":63,"end":73},"obj":"MOP:0000619"},{"id":"T834","span":{"begin":145,"end":155},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T833","span":{"begin":191,"end":201},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T832","span":{"begin":323,"end":332},"obj":"CHEBI:23888;CHEBI:23888"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T270","span":{"begin":321,"end":322},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T341","span":{"begin":20,"end":23},"obj":"Chemical"},{"id":"T343","span":{"begin":25,"end":29},"obj":"Chemical"},{"id":"T345","span":{"begin":35,"end":39},"obj":"Chemical"},{"id":"T347","span":{"begin":145,"end":155},"obj":"Chemical"},{"id":"T348","span":{"begin":191,"end":201},"obj":"Chemical"}],"attributes":[{"id":"A341","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_15422"},{"id":"A342","pred":"chebi_id","subj":"T341","obj":"http://purl.obolibrary.org/obo/CHEBI_30616"},{"id":"A343","pred":"chebi_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/CHEBI_16284"},{"id":"A344","pred":"chebi_id","subj":"T343","obj":"http://purl.obolibrary.org/obo/CHEBI_61404"},{"id":"A345","pred":"chebi_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/CHEBI_16311"},{"id":"A346","pred":"chebi_id","subj":"T345","obj":"http://purl.obolibrary.org/obo/CHEBI_61481"},{"id":"A347","pred":"chebi_id","subj":"T347","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A348","pred":"chebi_id","subj":"T348","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}

{"project":"LitCovid-sentences","denotations":[{"id":"T159","span":{"begin":0,"end":377},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"This enzyme prefers ATP, dATP, and dCTP as substrates; it also hydrolyzed all NTPs.[88] Toxicity issues are main obstacles in the development of inhibitors of helicase, and nonspecificity of inhibitors may cause serious toxicity.[87] However, despite theoretical limitations, helicase is being increasingly recognized as a druggable target for different disease conditions.[89]"}